Strides Pharma Science share news, announcements and annual reports
NSE: STARBSE: 532531Pharmaceuticals & BiotechnologySmall Cap
Strides Pharma Science Limited · Formerly Strides Shasun · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2000 on NSE, Jun 2004 on BSE
Last close ₹1,036.90down ₹31.90 (2.98%)BSE ₹1,037.80
Share price at the NSE close on 2 Nov 2026. Previous close ₹1,068.80.
2 Nov: open ₹1,067.30, high ₹1,067.30, low ₹1,013.90
52-week range of traded prices to 2 Nov 2026
₹768.65Low, 29 Jan 2026₹1,260.90High, 21 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹9,557 Cr580th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 15.50
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.80
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.48%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 20.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 13.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.53
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 4,07,98637.7% delivered
Strides Pharma Science shareholding disclosures
125 filed, newest first. Page 3 of 3.
Jul 2012
Apr 2012
Jan 2012
23 Jan · Disclosure
Compensation Committee of the Company has granted 100,000 options to an eligible employee under the Strides Arcolab ESOP 2008 Scheme at Rs.323.50 per option (exercise price). The shares covered by such options are 100,000 shares. The vesting period of these options is in a phased manner over a period of 3 years. The options may be exercised within a period of 30 days from the date of vesting.
Dec 2011
Nov 2011
Oct 2011
Sep 2011
6 Sep · Disclosure
Aug 2011
Jun 2011
May 2011
26 May · Disclosure
Compensation Committee of the Company has granted 9,000 options to eligible employees under the Strides Arcolab ESOP 2008 Schemes at an exercise price Rs.312.15 per option. The shares covered by such options are 9,000 shares. The vesting period of these options is in a phased manner over a period of 3 years. The options may be exercised within a period of 30 days from the date of vesting.
Feb 2011
9 Feb · Disclosure
Compensation Committee of the Company has granted an aggregate of 680,500 options to eligible employees under the Strides Arcolab ESOP 2006 and Strides Arcolab ESOP 2008 Schemes at an exercise price Rs.331.15 per option. The shares covered by such options are 680,500 shares. The vesting period of these options is in a phased manner over a period of 3 years. The options may be exercised within a period of 30 days from the date of vesting.
Sep 2010
3 Sep · Disclosure
Compensation Committee of the Company has granted 137,500 options to eligible employees under the Strides Arcolab ESOP 2008 Scheme at Rs. 353.95 per option (exercise price). The shares covered by such options are 137,500 shares. The vesting period of these option is in a phased manner over a period of 3 years. The options may be exercised within a period of 30 days from the date of vesting.
Jun 2010
15 Jun · Disclosure
Compensation Committee of the Company has granted 100,000 options to an eligible employee under the Strides Arcolab ESOP 2008 Scheme at Rs. 311.40 per option (exercise price). The shares covered by such options are 100,000 shares. The vesting period of these options is in a phased manner over a period of 3 years. The options may be exercised within a period of 30 days from the date of vesting.
Mar 2009
17 Mar · Disclosure
Remuneration Committee of the Company on March 17, 2009 has granted the following options: 1) 300,000 options under the Strides Arcolabs ESOP-2008 (Director) at Rs. 59.00 per option (exercise price) to a few eligible Directors of the Company. The shares covered by such options are 300,000 equity shares. 2) 100,000 options under the Strides Arcolab ESOP-2008 at Rs. 59.00 per option (exercise price) to an eligible employee of the company. The shares covered by such options are 100,000 equity shares.The vesting period of these options is in a phased manner over a period of three years. The options may be exercised within a period of 30 days from the date of vesting.
Feb 2009
10 Feb · Disclosure
Disclosure of Pledged shares in terms of SEBI (Substantial Acquisition of Shares & Takeovers) (Amendment) Regulations, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Oct 2008
31 Oct · Disclosure
Board of Directors have approved the introduction of a new ESOP Scheme titled 'Strides Arcolab ESOP-2008 (Directors)' for issuance of upto 500,000 Options, subject to applicable statutory/ regulatory requirements.
Mar 2008
10 Mar · Disclosure
The Board of Directors have approved the introduction of a new ESOP Scheme titled 'Strides Arcolab ESOP-2008' for issuance of upto 1,500,000 options, subject to applicable Statutory / regulatory requirements